Ipsen (Euronext: IPN) has reported a 16% rise in its revenue for the third quarter of 2022.
The French drugmaker’s quarterly sales total hit 775 million euros ($776 million), with the growth attributed to the 54% rise in sales of facial wrinkles treatment Dysport (botulinum toxin type A), helping to offset the slowdown in revenue from neuroendocrine tumors drug Somatuline (lanreotide).
"Our growth platforms have delivered a double-digit sales performance, reflecting improving commercial execution and the strength of our portfolio"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze